NCT02286843View on ClinicalTrials.gov

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

NACompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

November 6, 2014

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Breast Cancer MetastasesHER2 Positive Breast

Interventions

RADIATION

89Zr-trastuzumab

DEVICE

PET/CT scan

RADIATION

89Zr-pertuzumab

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

United States Department of Defense

FED

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER